Becotatug Biosimilar - Research Grade

Human

EGFR

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

ICH5378 is a research-grade biosimilar of Becotatug, supplied as an unconjugated, non-therapeutic analog built around the same epidermal growth factor receptor (EGFR) target as the originator antibody. The parent molecule is a fully human IgG1-kappa monoclonal antibody directed against the extracellular domain of human EGFR. This research-grade material is not a clinical drug and is intended strictly for research use only. It is manufactured to low-endotoxin specifications (research grade, less than 1 EU/mg) and is available in bulk milligram-to-gram quantities, making it suitable as an in-vitro standard, positive control, or benchmarking reagent in EGFR-focused workflows. Because it reproduces the target-binding characteristics of the originator without the therapeutic payload or clinical formulation, it is well matched to functional assays comparing EGFR-directed binders. As with all ichor.bio biosimilars, this product is provided as an analog for characterisation and comparison purposes and should not be interpreted as, or substituted for, the approved therapeutic. It offers a cost-effective, consistently supplied option for laboratories requiring a defined anti-EGFR IgG1 reference reagent. Epidermal growth factor receptor (EGFR, UniProt P00533; also known as ErbB1/HER1) is a receptor tyrosine kinase of the ErbB family. Ligand binding, by EGF, TGF-alpha, and related growth factors, drives receptor dimerisation and autophosphorylation of intracellular tyrosine residues, activating downstream RAS-RAF-MAPK, PI3K-AKT, and STAT signalling that governs cell proliferation, survival, migration, and differentiation. EGFR is expressed across many epithelial tissues, and its overexpression, amplification, or activating mutation is a well-established driver in numerous solid tumours, including nasopharyngeal, colorectal, head and neck, and non-small-cell lung cancers. This central role makes EGFR one of the most extensively targeted antigens in oncology, addressed by monoclonal antibodies against its extracellular domain and by small-molecule kinase inhibitors, and a frequent subject of binding, blocking, and receptor-internalisation studies.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks